Business Wire

MA-OMEGA-ALPHA-SPAC

6.1.2021 23:27:26 CET | Business Wire | Press release

Share
Omega Alpha SPAC Announces Pricing of Its Initial Public Offering

Omega Fund Management’s special purpose acquisition corporation, Omega Alpha SPAC, announced the pricing of its initial public offering of 12,000,000 Class A ordinary shares, par value $0.0001, at a price to the public of $10.00 per share, for aggregate gross proceeds of $120,000,000. The shares are expected to begin trading on the Nasdaq Capital Market on January 7, 2021 under the symbol “OMEG”. The offering is expected to close on January 11, 2021, subject to customary closing conditions.

Omega Alpha SPAC, sponsored by an affiliate of Omega Fund VI, L.P., is a newly incorporated blank check company, incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to as our initial business combination. Omega Alpha SPAC expects that its focus will be on the biotechnology sector in developed countries including, but not limited to, the United States and countries in Europe.

Jefferies LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for the offering. Omega Alpha SPAC has granted the underwriters a 45-day option to purchase up to an additional 1,800,000 Class A ordinary shares at the initial offering price to cover over-allotments, if any.

The offering of these securities is being made only by means of a prospectus. Copies of the prospectus relating to this offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by e-mail at prospectus_department@jefferies.com or by telephone at 1-877-821-7388 or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014.

A registration statement relating to the sale of these securities was filed with, and declared effective by, the Securities and Exchange Commission on January 6, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to Omega Alpha SPAC’s offering and search for an initial business combination. No assurance can be given that the offering will be completed on the terms described, or at all. Forward-looking statements are subject to numerous risks and conditions, many of which are beyond the control of Omega Alpha SPAC, including those set forth in the Risk Factors section of Omega Alpha SPAC’s registration statement relating to the offering. Omega Alpha SPAC undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Intersolar Europe: European Solar Industry Responds to Market Changes: Focus on Hybrid PV and New Financing Models24.2.2026 14:30:00 CET | Press release

The European solar market continues to grow. According to SolarPower Europe’s latest European Market Outlook, 2025 marked another strong year for photovoltaics (PV) within the European Union. When it comes to annual expansion rates, Germany is at the top of the list, followed by Spain, France, Italy and Poland. The importance of solar energy in meeting Europe’s power needs continues to grow. At the same time, many countries are changing their subsidies and financing models, creating new challenges for investors. While regulatory instruments, such as contracts for difference (CFDs), provide a new order, the industry is responding with market-based solutions, such as hybrid PV power plants and hybrid power purchase agreements (PPAs). Intersolar Europe offers guidance: At The smarter E Europe, Europe’s largest alliance of exhibitions for the energy industry at Messe München, trade visitors can experience innovations, discuss new business models and meet project developers, manufacturers a

LMR Unveils Tonka Bean CO₂ Absolute: Gourmand Excellence from Planet-Friendly Extraction24.2.2026 14:15:00 CET | Press release

True-to-nature gourmand richness achieved with renewable CO2 technology. IFF (NYSE: IFF) — LMR Naturals by IFF—a global leader in natural ingredients for perfumery, cosmetics and flavors—has introduced Tonka Bean CO₂ Absolute to its Conscious Collection, a line of 12 highly sustainable and traceable natural ingredients for perfumes and flavors. Tonka Bean CO₂ Absolute is a natural extract with a gourmand olfactive signature. This new addition to the perfumer’s palette is produced with renewable and recycled supercritical CO2 at IFF’s extraction site in Aubrac, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224233830/en/ Tonka Bean CO₂ Absolute extracted by LMR. “Our CO₂ extraction unit in Aubrac has enabled LMR to develop a collection of extracts that seamlessly blends sustainability with high hedonic profiles for perfumers," said Bertrand de Préville, general manager of LMR Naturals by IFF. "With the launch of To

NorthX Biologics and Demeetra Announce Strategic Collaboration to Deliver a Faster, Lower-Risk Path from Gene to GMP24.2.2026 14:00:00 CET | Press release

NorthX Biologics and Demeetra today announced a strategic collaboration combining a best-in-class high-titer GS (-/-) CHO cell line with full freedom to operate and no additional IP-related costs, together with advanced cell line development technologies and high-quality process development, MCB banking, and GMP manufacturing services. The collaboration is designed to help biotech companies reach IND-enabling and clinical milestones faster, with fewer technical setbacks and without the need to rebuild cell lines or re-qualify processes when transitioning to a manufacturing partner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224427714/en/ Supporting stable, high-titer cell line development and seamless GMP advancement. The partnership combines Demeetra’s CleanCut™ CHO platforms and stable CLD services with NorthX Biologics’ proven GMP production capabilities, process scale-up expertise including fill and finish, and re

AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 202624.2.2026 14:00:00 CET | Press release

-- The trial uses a response-driven dosing strategy and extended treatment across three prostate cancer populations, supported by the favorable clinical, pharmacokinetic and dosimetry results from Phase 1b -- AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the novel Phase 2 design of the ongoing TheraPb clinical trial of ADVC001 in metastatic prostate cancer. ADVC001 is an investigational Lead-212-based prostate-specific membrane antigen (PSMA)-targeted alpha therapy. The study design will be showcased in a ‘Trials in Progress’ poster this week at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) in San Francisco, CA. The TheraPb Phase 2 is an open-label, randomized expansion study incorporating dose optimization strategies in three groups of patients with metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC). The study’s innovative d

Axelera AI Secures More Than $250 Million Funding on Global Commercial Growth24.2.2026 14:00:00 CET | Press release

European AI semiconductor leader earns backing from funds managed by Innovation Industries and SiteGround Capital along with EU institutions; edge-first architecture addresses AI's critical energy and cooling constraints Axelera AI, the European leader in AI acceleration hardware, announced its latest funding round led by Innovation Industries, with participation from prominent funds and accounts including BlackRock and SiteGround Capital as new investors, as well as existing investors Bitfury, CDP Venture Capital, European Innovation Council Fund, Federal Holding and Investment Company of Belgium (SFPIM), Invest-NL, Samsung Catalyst Fund, and Verve Investments. Axelera AI has attracted over $450 million in equity, grants and venture debt since incorporating in July 2021. The largest investment ever in an EU AI semiconductor company comes as Axelera ships to its 500th global customer across physical AI and edge AI in industries including defense and public safety, industrial manufactur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye